ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John Kern
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kern, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kern, J.
Related Collections
Right arrow Cerebral protection

Ann Thorac Surg 2005;80:2249
© 2005 The Society of Thoracic Surgeons

Original article: Cardiovascular

Invited commentary

John Kern, MD

Department of Surgery, University of Virginia Health Sciences Center, Box 181-95, Charlottesville, VA 22908

(Email: jak3r@virginia.edu).

The first 20% of the full text of this article appears below.

Kaplan and colleagues [1] have found another pharmacologic intervention to protect the fragile spinal cord against ischemia reperfusion (IR) injury in a laboratory model. During the past 2 decades many drugs have been discovered to protect against such injury in animal studies, but time and again these agents have not been translated into clinical efficacy for humans. As much as we know about the pathophysiology of IR injury in numerous organ systems, an effective treatment for spinal . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.